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1. Introduction   
Medulloblastoma (MB) is an embryonal brain tumor of the cerebellum. MB accounts for 4- 
6% of all primary intracranial tumors. It is the most common malignant brain tumor in 
children it represents 15-30% of all pediatric brain tumors, with 85% of MBs being 
diagnosed in patients younger then 18 years of age. The peak incidence occurs between the 
ages 3-9 years, with about  35% metastasis disease(Crawford et al., 2007; Polkinghorn and 
Tarbell 2007; Rossi et al., 2008).  
In contrast, medulloblastoma is rare in adults and accounts for less than1% of primary 
intracranial malignancies in this age group (Brandes et al 2009; Louis 2007; Padovani  et al 
2007).  
Based on histopathological features, the 2007 WHO classification of CNS tumors (Louis et 
al.,2007; Gilbertson and Ellison 2008), has separated  MB into five recognizable subtypes:  
the classic tumor which is the most common subtype of MB in general and in children in 
particular. The other four variants are: 1. desmoplastic/nodular which is the second most 
common (10-20% of the cases) in very young patients and adults, 2. MB with extensive 
nodularity is predominantly observed in infants (less then 3 years old), 3. anaplastic MB,  4. 
large cell MB  is rare in infants, both of  which account for 5-10% of the cases 
The histological classification and clinical staging have proven to be less then ideal methods 
for stratification. Histological subtypes are often quite heterogeneous and exhibit highly 
variable clinical behavior, with anaplastic subtype typically associated with the worst 
prognosis, followed by classic and desmoplastic\nodular MB, which correlate with 
improved overall survival.  
MB with extensive nodularity and desmoplastic/nodular MB in infants have a better 
outcome than the classic MB tumors, while large cell and anaplastic MB behave 
aggressively. Thus infants with desmoplastic MB should be stratified into a low risk 
therapeutic group while the large cell MB is rare but points to a poor prognosis that often 
presents with metastatic disease (Gilbertson and Ellison 2008).  
The increasing recognition of MB as a heterogeneous disease, with histological and 
molecular variants that have distinct biological behavior, affected the disease classification 
and treatment.  
In spite of current aggressive therapies, approximately one third of the patients eventually 
succumb to the disease due to metastasis. Furthermore the post- treatment squeal, which 
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includes neurological, vascular and long-term neurocognitive impairments, can be 
devastating for survivors of the disease (Ribi et al., 2005).  
It is imperative to gain a better understanding of the molecular alterations and other 
biological squeal in medulloblastom for future targeted therapies that are more effective and 
less toxic. 
A combination of clinicopathological evaluation and assays based on molecular subgroups 
of the disease allow stratification of patients into risk groups and more tailored approach to 
therapy which should prevent the significant adverse effects among survivors.  
Studies in the last 5 years have helped to build a consensus on the value and means of using 
molecular markers in the therapeutic stratification of childhood medulloblastoma 
(Gilbertson 2004 ; Packer and Vezina 2008 ; Pizer and Clifford 2009). 
These studies have revealed the genetic heterogeneity within MB including dysregulation of 
several signaling pathways. The genetic heterogeneity appears to be the basis for differential 
response to treatment and give a new impact to the traditional histological subtyping and 
improve to some extend the accuracy of diagnosis and prognosis and as a consequence the 
stratification to risk groups (Packer and Vezina 2008). 
Although, adult MB is considered different from their childhood counterparts in terms of 
tumor biology and clinical variables, yet, because of the high incidence of MB in childhood 
and low incidence in adults most of the studies have been done on the MB of childhood. 
Some studies documented differences between childhood and adults tumors with regards to 
localization, cell of origin, histopathologic features, tumor cell differentiation, and treatment 
outcome. The adult's MB found to be also genetically distinct from the pediatric MB 
(Korshunov et al 2010).  
Here we focused on the genetic alteration reported so far in MB and their significance in 
sub-typing, stratification, and medical care.  
2. Heritability of medulloblastoma  
Neither familial cases of MB, nor MB's cases affected by defined environmental factors have 
been described so far. Also, no specific chromosomal aberration has been described in more 
then about 40% of the MB cases. Unlike Ewing sarcoma, where t(11;21) can be found in 
about 90% of the cases, in MB no main specific gene alteration can be detected. Yet, there is a 
wide basis to believe that inheritable factors play a significant role in MB pathogenesis and 
prevalence. Some of the evidence that support this point of view are:   
A. Age of onset- MB is most prevalent in childhood including about 3% in infancy, mainly 
medulloblastoma with extensive nodularity, while it is rare in adults. MB is mostly a 
childhood brain tumor with a peak in 3-9 years age. Inheritable markers are most probably 
expressed phenotypically at the early ages of life. The younger the patient is, the higher 
chance that the genetic part is more pronounced, and so in the adults, the latter the age of 
tumor appearance the higher chance for multi-factorial environmental cause. About 85% of 
the primary intracranial tumors diagnosed as MB in patients younger then 18 years of age 
while in adults about 1% of the primary intracranial tumors diagnosed as MB. It is well 
known that infants are the more vulnerable group with 25-60% rate of cure, while the over 
all 5-year survival rate in childhood is about 80%. Although, the environmental factors 
could not be totally excluded, yet the younger age of MB appearance with 35% metastatic, 
points toward a more pronounced genetic background rather then environmental (Rossi et 
al 2008, Bar and Stearns 2008).  
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B. Severity of the disease- the most prevalent MB sub-type in infancy is the desmoplastic 
which is considered the most aggressive sub-type especially when it also appear with 
metastasis , 35% of the childhood MB are metastatic at presentation. Metastatic phenotype 
considered as a high risk group with the worst prognosis. Cure rates are lower for infants 
than for older children. This might point either to the more significant-effective role of the 
inheritage genetics predisposition in infants then in elderly or adults MB. Also most 
probably radiotherapy can be particularly more adverse in the immature infant brain (Grill 
et al 2005; Packer and Vezina 2008; Rutkowski et al., 2009). The main consequence of 
carniospinal irradiation (CSI) is notably cognitive problems children's IQ can decrease by as 
much as 30 points in the standard risk group. The high risk group (metastasis, significant 
post operative residual tumor) remains poor 5-years event free survival (EFS) being 25-40% 
the worse prognosis is particularly in younger children 
Although 5-years overall survival rates have reached 60-80% , survivors often face a variety 
of long term neurological , neuroendocrine , and social squeal as a result of conventional 
treatment regimens (surgery, radiotherapy, and chemotherapy (Pizer and Clifford 2009)  
(Packer and Vezina 2008; Rossi et al 2008, Bar and Stearns 2008). It is imperative to gain a 
better understanding of the molecular alterations in MB for future targeted therapies that 
are more effective and less toxic.  
C. Predisposition- Predisposition to develop MB due to known genetic alterations- some 
MB cases are associated with known hereditary syndromes such as Gorlin,  Turcot and Li-
Fraumeni. (Reviewed by Ellison 2010, Northcott, 2011; Onvani 2010) will be discussed in the 
gene alteration part. All the above points support the suggestion that genetic factors cause 
predisposition for MB's development.  
Most studies on MB have focused on genes that are already known to be involved in the 
pathogenesis of tumors, such as Wnt, SHH, Notch TP53. The specific genetic pathway/s in 
MB is/are still unknown.  
Studying the different MB's subtypes with the most advanced technologies will significantly 
contribute to the overall understanding of  MB pathogenesis in general and in particular  in 
MB genetic knowledge. 
3. Chromosomal aberration and its corroletion to clinicohistopatological 
classification 
Cytogenetics and molecular genetics are two different levels of genetic studies. Both of them 
are in use for characterization of tumors in general and MB in particular. Nowadays, these 
tests in combination with other standard methods such immunohistochemistry, significantly 
improved the diagnosis, prognosis  and consequently the treatment modalities and survival of 
the patients with malignant diseases. Cytogenetics, molecular cytogenetics (FISH, CGH ) and 
molecular genetics are three methods that supplement each other, and their combination leads 
to the identification of the genes that are involved in tumorigenesis (tumor suppressor genes 
and oncogenes) and thus can give complete information for prognostic and diagnostic 
purposes. Although, impressive progress has been achieved in the nano molecular genetics, 
next generation sequencing, proteomics and transcriptomics, in the last decade, yet, we can not 
give up the "macro-tests":  the old gold standard methods such as cytogenetics and histology. 
The nano tests are still new and very expensive to implicate to routine work up, they are in a 
developing stage and the accumulated experience with their use is still limited. There is still 
missing information regarding the whole range of polymorphism and how to differentiate it 
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from significant changes. Also the exact interactions between all the nano tests (molecular 
genetics, proteomics and transcriptomics) are only partially understood so far. Moreover the 
significance and the importance of the immerging field of epigenetics is still not clear. The field 
of epigenetics is dealing with changes that do not affect the molecular genetics itself but rather 
the changes in the expression of the gene/s by changing mythlation, acetylation, 
phosphorilation and ubiquitination (Bernstein et al. 2007; Kouzarides 2007). Its effects include 
the most delicate interactions of all the living levels, starting from biochemical reaction and the 
interactions inside the cell compartments, cell to cell, in the organ, in the host and between the 
host and the environment.  
Chromosome analysis of tumor cells plays an important role in the diagnosis, prognosis and 
follow up of many malignancies. It is a standard of care in hemato-oncology. Culturing solid 
tumor cells in vitro is essential for cytogenetic analysis. The success in getting specific 
chromosomal aberrations in solid tumors after in vitro culturing is limited because of 
technical problems such as: an overgrowth of cells from healthy part of the tissue mostly 
fibroblasts, limited growth of the abnormal tumor cells and low quality of the tumor cell 
metaphases and also the need for special and well trained cytogeneticists. These are 
probably the main reasons for the limited and what seems like a non specific chromosomal 
aberration in medulloblastoma. Only about 40% of the medulloblastomas demonstrate 
chromosomal aberrations. Presently, advanced technologies such as microarray CGH and 
next generation sequencing enable us to better evaluate chromosomal aberrations in 
medulloblastoma. It will take some time for the accumulation of new data regarding 
chromosomal aberrations using the new methods, mainly because reliable results should be 
done on a large cohort which include sufficient size group of all MB subtypes.  
Copy number abnormalities of chromosome 17 isodicentric, isochromosome of chromosome 
17q, loss of 17p, or gain of 17q  are the most frequent chromosomal abnormality in 
medulloblastomas (Mitelman database 2011, Aldosari et al 2002;  McCabe et al 2006)  it is 
found in 30-50% of the studied cases (Reardon et al 1997). Isochromosome –isodicentric 
chromosome 17 is present in approximately one third of the tumors and in some cases is the 
only chromosomal aberration (Mitelman database 2011; Pfister et al 2009; Ricket and Paulus 
2004). It has been observed in 25-30% of childhood MB. In fact there is a loss of 17p and a 
gain of 17q which is the most common isochromosome in cancer in general (Mitelman 
database 2011). This might point toward the fact that i(17q) is a general marker of neoplastic 
process rather then a specific marker of MB. Its role as an indicator for a poor outcome in 
MB stratification is controversial. The controversial evidence based mainly on the findings 
of i(17q) also in Wnt pathway subgroup which in consensus considered as a favorable 
outcome. The question whether to consider copy number abnormality of chromosome 17 as 
a marker for poor prognosis and to exclude those found to be Wnt  pathway, is still in 
debate (Pan et al 2005; Pfister et al 2009).  
Using more sophisticated and advanced techniques such as CGH to profile a panel of 27 
primary MB (Reardon et al 1997) revealed frequent loss of 10q, 11, 16q, 17p, and 8p as well 
as recurrent gains of  chromosomes 7, and 17q. These losses and gains were also confirmed 
by other techniques, such as G-banding, SKY and FISH (Aldosari et al 2002; Avet-Loiseau et 
al 1999 ; Bayani et al 2000; Eberhart et al 2002; Gilhuis et al 2000). Array CGH of 47 MB 
(Speicher and Carter 2005) showed gain of 17q, 7, and 1q and loss of 17p, 11p,10q and 8.  
There have also been reports, although less frequently of losses on chromosomes 10q, 11, 
17p qnd 22 as well as gains on chromosomes 1q, 7 and 7q (Mitelman database 2011; Bayani 
et al 2000).  
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SKY analysis of 19 primary MB revealed structural aberrations involving chromosomes 7, 
17, 3, 14, 10 and 22.(Bayani et al 2009).  
 Monosomy 6 is strongly associated with Wnt profile in MB (Clifford et al 2006). 
Chromosomal abnormalities including loss of chromosome X in females and loss of 
chromosome 8, have been found mainly in non SHH/Wnt subgroups.  
4. Genetic alterations and its corroletion with clinicohistopatological 
classification 
Tumorigenesis is a process in which one of the pathways leading to normal cell 
development has lost its control and its normal function. In addition, the neovasculization, 
cell proliferation, differentiation, motility and apoptosis (death) are also altered.  
There are two possible categories in tumor specific genetic alteration; one is inheritable or 
germ cells mutation and the other is acquired alteration. Also there is a difference between 
general tumorigenesis pathways and tumor specific pathway and general chromosomal 
aberration and tumor specific chromosomal aberration.  
Usually, the tumor specific pathway is a part of the general tumorigenesis pathways but still 
it is predominant in one specific tumor subgroup, for example RB gene that causes mainly 
retinoblastoma, WT gene that causes mainly Willm's tumor, both are also causing 
predisposition to other tumors. Similarly, the acquired gene alteration occurring during the 
life time, such as BCR/ABL is causing chronic myeloid leukemia and EWSR1-FLI1 is 
causing Ewing sarcoma. Specific acquired aberration found in addition to the cancer they 
caused, also in other cancers ,  there its significance and  its prognostic value is different, for 
instance BCR/ABL points to a favorable prognosis in CML and points  to a poor prognosis 
in acute lymphocytic leukemia (ALL).  
Among the life time acquired mutation, one should differentiate between the first event, 
such as alteration of a gene that causes the disease and has a diagnostic value and those 
mutations that are considered as the latter (the second or the third) events for example 
KRAS and TP53 mutation in adenomatose polyposis coli (APC) and MNP1 or FLT1 
mutation in acute leukemia. Those gene alterations have mainly prognostic value and may 
play as a general event seen in other tumors as well.   
Unfortunately, neither MB specific chromosomal changes nor MB specific gene were found 
to be a clear evidence for the possible pathogenesis of MB, neither in MB general nor in one 
of its subtypes. The understanding of MB pathogenesis is still limited, mainly because most 
of the MB studies are associated with genes that are already known to be involved in other 
tumors or syndromes, rather then studying the MB specific gene alterations as the first goal.  
Indeed, MB is associated with other (tumor's) syndromes such as Gorlin,Turcot and Li 
Fraumeni, in which several important developmental signal transduction pathways, 
including sonic hedgehog (SHH), Wingless (Wnt) and Notch signaling cascades. SHH, Wnt, 
TP53  and Notch signaling cascades are implicated in the cells migration and localization in 
the cerebrum,  and their proliferation and differentiation. The alterations in these pathways 
by any component of each signaling pathway may lead to tumorigenesis (Marino 2005; 
Ingham and Placzek 2006). For example, Gorlin's syndrome characterized by a germ line 
mutation in the patched homologue 1 (PTCH1) located on 9q22 ( Frandon et al 1992 ) that 
served as a negative regulator of SHH gene during normal cerebella development. Mutation 
in PTCH1 gene can cause predisposition to different tumor development including MB with 
incidence of 5-20% (Friedrich 2007). 
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Turcot syndrome is characterized by the mutation in the APC a tumor suppressor gene that 
is predisposed mainly (about 90% during life time) to colon cancer adenomatous polyposis 
coli (APC), (Hamilton et al 1995) but also predisposed to a lesser extend  to other tumors 
including MB (Huang et al 2000). The APC gene regulates the Wnt signaling pathway.  
Recent advances in gene expression profiling techniques have led to the generation of 
several molecular classification schemes in MB (Thompson et al 2006; Kool et al 2008; 
Northcott et al 2010 epub). 
In general, based on the molecular studies done so far, three main subgroups were defined: 
SHH, Wnt and non SHH/Wnt pathways which include another 2 subgroups which are less 
distinct (Thompson et al 2006; Kool et al 2008; Onvani et al 2010; Ellison 2010; Northcott et al 
2011). SHH pathway subgroup accounts for 15-25% cases of MB and have a poor 
prognosis,Wnt pathway subgroup accounts for 15-20% cases of MB and mostly has 
favorable prognosis, and non SHH/Wnt subgroups account for 60% cases of MB.  
According to the Thompson's (2006) classification based on molecular and FISH 
examination 5 distinct subtypes identified (A to E) including subgroup B in which Wnt 
pathway and monosomy 6 have been found and subgroup D in which SHH pathway has 
been found. Kool et al (2008) further corroborated Thompson's classification using CGH and 
defined 5 subgroups: (A)-Wnt signaling subgroup, (B)-SHH signaling pathway, C and D 
expression of neural differentiation genes, D and E expression of photoreceptor genes. 
Subgroups C, D and E are genetically closely related and most often associated with 
metastatic appearance mainly subgroup E.   
SHH pathway MB associated with desmoplastic phenotype (Behesti 2009) and also  with large cell 
and anaplastic MB. They are both reported mainly in infancy and childhood. Metastatic 
disease at presentation characterizes some SHH pathway mostly large cells and anaplastic MB. 
Less then half of the SHH pathway MB have PTCH1 mutations or show copy number loss at 
the PTCH1 locus, 9q22, mutations in SMOH and SUFU are rare thus there must be other 
undiscovered SHH pathway/s (Thompson et al 2006; Kool et al 2008; Northcott et al 2011).  
In contrast Wnt pathway is mostly associated with classic MB (Fattet et al 2009) it has a 
favorable outcome it tends to be present in childhood in the pre-teen years (6-13 years) but 
almost do not present in infancy. Most of the children with this tumor survived ( Thompson 
et al 2006). Metastatic disease at presentation is rare in Wnt pathway. There is no report on 
desmopastic medulloblastoma with Wnt pathway and also large cell and anaplastic MB 
with Wnt is rare. The APC protein is a regulator of Wnt signaling that function in a complex 
with other components to regulate several important developmental processes, including 
proliferation and specification of neural progenitor cells during early cerebellar 
development (Sillitoe and Joyner 2007). APC function as a tumor suppressor through 
CTNNB1 (β-catenin) of sporadic cases of MB, a downstream component of the Wnt 
signaling pathway (Hamilton et al 1995) this account for 15% of the cases. β-catenin  by itself 
also activates transcription of several oncogenes such as MYC and CCND1 resulting in 
enhanced cell proliferation (Ellison et al 2005). 
Only a small part of the Wnt pathway MBs are found to be carrying mutations in CTNNB1 
gene-captured by identification of the nuclear activity of β-catenin in the MB. Mutations in 
APC and AX1N1/2 are rare, thus there are still undiscovered components also in Wnt 
pathway (Ellison et al 2005; Fattet et al 2009; Norhcott et al 2011).  
Most of non SHH/Wnt MBs have a classic pathology and present in infancy and childhood. 
About half of the large cell and anplastic MBs are non SHH/Wnt. Metastatic disease at 
presentation also falls into the non SHH\Wnt tumor subgroup.  
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Other molecular markers beside the above three identified groups is the amplification of 
MYC family (MYC and MYCN proto-oncogenes), that account for 4-15% of MBs (Rossi et al 
2008; McCabe et al 2006). MYCN is an early transcriptional target of the SHH pathway and 
activation by SHH promotes the expression of the cell cycle proteins cyclinD1 and CyclinD2 
leading to GCP proliferation (Behesti amd Marino 2009). A high expression level of MYC is 
reported to cause progression of MB to an anaplastic phenotype and has been linked to a 
poor prognosis while even though MYCN shows some association with large cells and 
anaplastic MB yet it is less established as a marker for an adverse outcome (Aldosari et al 
2002; Pfister et al 2009). 
Both SHH and Wnt subgroups rarely show copy number abnormalities of chromosome 17, 
amplification of MYC and MYCN or any other widespread ploidy changes. MB occurred 
also in 5% of the Li Fraumeni syndrome's patients carrying mutation in the suppressor gene 
TP53 (Northcott 2009). Other known pathways are involved in the normal cerebellar 
development found also to be aberrant in some of the MB. For example a disturbance of the 
RAS-MAP upregulation through downstream components such a MAP2K1,MAP2K2, and 
MAPK1/3. It is found to be correlated with metastatic behavior (Gilbertson and Clifford 
2003). Also, overexpression of the EGF receptor family member ERBB2 is linked to 
metastatic behavior. A number of proto-oncogenes in MB such as CDK6, PDGFRA, KIT and 
MYCL1 have been found to be amplified by array CGH. A single copy numbers gains of 
MET locus on chromosome 7q in 38.5% of the cases in 13 MBs (MacBabe 2006; Tong et al 
2004). 
The Notch pathway was found to be implicated in MBs pathogenesis in a number of studies. 
Notch promote granule cell precursor (GCP) proliferation and prevents their differentiation 
( Behesti and Marino 2009). Increased copy number of Notch2 has been found in 15% of the 
studied MBs. Also, mutated  Hes1 gene that unregulated the Notch  pathway have been 
found in a small study group, although it has been associated with poor prognosis and 
outcome, its role and  implication should be carefully considered and further examined (Fan 
et al 2004; Thompson et al 2006; Kool et al 2008; Northcott et al 2009).  
Due to technology limitations and the availability research strategies most molecular studies 
of MBs , we are still missing the  MB specific molecular markers. Hopefully, MB subtypes 
specific markers will be discovered by using the advanced technologies which enables us to 
study MB at different levels: DNA by next generation sequencing, gene expression by 
transcriptomic and protienomic, epigenomic and miRs.  
An accurate classification and the stratification will implicate the medical care. An optimal 
classification will differentiate between MB in each age interval (infancy, childhood and 
adult) and between the subgroups in each age.  
There is a general consensus that a better understanding of the disease biology should allow 
us to develop more effective and less harmful treatments of MB. 
Northcott et al (2011) generated a class prediction algorithm, an 8-gene classification model 
which successfully predicted the survival status for 47 out of the 60 patients profiled. The 
markers of the cerebellar differentiation (β-NAP, NSCLI, TRKC) and component of the 
extracellular matrix (lysyl hydroxylase[PLOD], collagen TypeVai and elastin) predict  
favorable prognosis. While genes involved in cell proliferation and metabolism (MYBL2, 
enolas 1, LDH, HMGI[y], and cytochrome C oxidase) as well as ribosomal protein coding 
genes predict poor prognosis.  
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5. MicroRNA (miR) and its corroletion with clinicohistopatological 
classification 
The field on miRNA emerged in the last few years, concentrates on small non coding, single 
strand RNA molecules that are found to play a regulatory role on gene expression.  
Differential microRNA (miR) expression analysis has also contributed to our knowledge on 
MB pathogenesis. The miRs are the short fragments of endogenous noncoding RNA that 
play an important role in the developmental processes by regulating gene expression. Target 
mRNAs are either degraded or translationed by specific miRNAs. Ferretti et al (2008) 
performed one of the earliest expression profiles on MB. Northcott et al (2009) identified 
amplification of miR17/92 polycistron proto-oncogen in 6% of pediatric MBs and showed 
upregulation of miR17/92 expression in a large percentage of primary cases. Similarly, 
Pierson et al. (2008) demonstrated decreased expression of miR-124a in primary MB as well 
as in MB cell line. Onvani et al (2010) have reported that miR124a as a negative regulator of 
CDK6 which are found to be overexpressed in MB (Mendrzyk et al 2005). Additional 
oncogenic targets, such as miR-30b and miR-30d have also been proposed through miRNA 
profiling ( Lu et al 2009 )   
Northcott et al (2009) have described subgroup classification based on transcription profile, 
using mRNA and miRNA examination. They identified 4 distinct subgroups including the 
well known Wnt and SHH and another two independent subgroup C and D. It has been 
found that mir17/92, cluster of oncogenic miRNAs, was highly expressed in SHH tumors in 
association with MYCN expression, while group C was found to be correlated with MYC.  
High–resolution SNP array profiling on a group of >200 MB revealed high–level 
amplification of miR-17/92 on 13q31 (Northcott et al 2009).  
It has been found that miR-17/92 and related paralogs (miR-106a/363 and miR-106b/25) 
were identified as the most highly upregulated miRNAs in MB when compared with 
normal cerebellum in this analysis. The combination of miR 17/92 amplification and 
consistent overexpression suggested miR-17/92 as a key player in MB pathogenesis. There 
is evidence that miR17/92 might cooperate with SHH in MB, as it showed preferential 
upregulation in SHH subtype. 
Recently the role of miRNA  in MB has been studied on 14 primary cases using profile of 248 
miRNAs showing a general biased downregulation in MB cells as compared to the control 
cells . A subset of 86 miRNAs which were previously reported to be expressed in neuronal 
tissues and/or cancer studied in cohort of 34 among them two neuronal candidates miR-9 
and miR-125a were chosen for functional analysis. Induction of their expression resulted in 
the decrease in tumorigenic features: promoted apoptosis, inhibited cell proliferation and 
impaired anchorage-independent growth. Moreover loss of miR9 and miR125a correlated 
well with upregulation of truncated trkC which was identified as a target for 
posttranscriptional repression (Northcott 2009). 
In order to discriminate between miRs deregulation in SHH–driven MB from non SHH-
cases, 31 MBs studied using a set of 250 miRs. Two groups were defined GLI1-high and 
GIL1-low. A set of 34 miRs was found with a significant differential expression between the 
two classes. For functional analysis of the GLI1-high class three candidates (miR-125b, miR-
324-5p, and miR-326) exhibiting reduced expression were chosen based on their predicted 
capacity to target the SHH family members, Smo and Gil1. They were proven to repress 
Smo mRNA level in the MB cell line (Ferretti et al 2008).  
SNPs array profiling of more then 200 MB revealed copy number aberration of multiple 
unreported regions including high level amplification of miR17/92  
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Another miRNAome study of 90 MB revealed that four distinct molecular subgroups can be 
described. These subtypes include the well characterized Wnt and SHH subgroups and 
another 2 subgroup designated C and D (Northcott et al 2009).  
The miR-17/92 was the most highly expressed in SHH-driven MB but also in tumors 
exhibiting high MYCN (SHH) and MYC (group C,Wnt) expression. MiR-17/92 
transcriptional upregulation by N-Myc and Myc and confirming miR-17/92 aberrancy in a 
large percentage of the MBs ( about 60%). Based on experiments on mice it was suggested 
by Northcott et al (2009) that miR 17/92 cooperate with SHH signaling to promote and/or 
enhance CGNP proliferation.  
The miRs studies are still in their initial stage and we are still far from understanding their 
exact role and how they affect processes in MB pathogenesis. 
6. Epigenomic and its corroletion with clinicohistopatological classification 
Until recently the thought was that genetic alteration is the main cause of each tumor 
development and progress. Researchers invest their efforts in finding a tumor specific 
pattern of genetic alteration. Over the past few years another aspect has arisen which is the 
deregulation of epigenetics to malignancy (Jones and Baylin 2002;Bernstein et al 2007; 
Kouzarides 2007; Kongham et al 2008; Esteller 2008). 
Epigenetics involves nongenetic DNA modifications that result in changes in gene expression. 
These changes include gene promoter mythylation on cytocine residues, most frequently of the 
CpG islands of the promoter, as well as their histone code. These changes are found to be 
involved in pathogenesis of tumors including MB, through hypermethylation of promoter of 
tumor suppressor genes and consequently silencing them (Kongham et al 2008).  
Fruhwald et al (2001) showed methylation of up to 1% of all CpG island in 17 primary 
medulloblastoms, it was linked to poor prognosis.  
Epigenetics is defined as "mitotically heritable changes in gene expression that are not 
accompanied by modifications in primary DNA sequence". It is highly correlated with the 
MB class were ZIC and NSCL1 , encoding transcription factors that are specific for cerebellar 
granule cells point to the MB arised from cerebellar granule cells. 
Anderton et al(2008) have identified tumor –specific methylation of COL1A2 in 77% of the 
studied primary MBs (46 out of 60) and showed an age-dependent methylation pattern for 
this gene in desmoplastic tumors, which presented COL1A2 as a potential MB subtype 
biomarker. Kongkham et al. (2008) identified serin protease inhibitor kuntiz-type2 
(SPINT2/HAI-2), an HGF/cMET signaling inhibitor, as a novel tumor suppressor gene that 
is frequently silenced by promoter hypermethylation in MBs (Kongham et al 2008). Also 
Waha et al (2007) found promoter hypermethylation-induced reduction of SCG5 expression 
in primary 16 out of  23 primary cases compared to normal cerebellar controls ( Waha 2007), 
points to its possible role in pathogenesis of MB. Furthermore, promoter hypermethylation-
mediated silencing of CASP8, HICI and RASSF1A tumor suppressor genes has also been 
discovered in more than 30% of MBs by various groups (Lindsey et al 2004).  
Pfister et al (2007) showed a striking association between samples classified as either "low 
methylators" or "high methylators" and patient outcome, where the "high methylators" 
group exhibited reduced overall survival.  
Also the GLI C2H2-type zing-finger protein family member ZIC2 was identified as 
hypermethylated and thus it has been silenced (Pfister et al 2007).  
It has been found that EHMTI  function as part of a transcriptional repressor complex that 
mediates gene silencing by promoting dimethylation of H3K9 (Tachibana et al 2005), a 
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repressive epigenic modification (Bernstein et al 2007; Kouzarides 2007) in the promoter 
regions of target genes. An obvious correlation between loss of EHMTI leads to H3K9 
hypomethyelation. 
Another study using microarray-based differential methylation hybridization (Waha et al 
2007) identified hypermethylation of the SCG5 (secretory granule, neuroendocrine protein 
1[7B2 protein] gene) in 16 out of 23 (70%) primary MB. Expression of SCG5 found to be 
downregulated in the MB in comparison with normal cerebral controls. Another gene that 
found to be down regulated is SPINT2 that was found in 41 out of 56 primary MB. Stable 
expression of SPINT2 resulted in attenuation of the malignant phenotype: inhibiting cell 
proliferation, anchorage-independent growth in soft agar and cell motility, of cell lines 
(Kongham et al 2008). This study suggested that SPINT2 is a suppressor gene. Treatment of 
MB cell lines suggesting that SCG5 is a suppressor gene (Fruhwald et al 2001) or increased 
gene with demethylation agent (5-aza-2'deoxycytidine) reduced colony formation 
expression (Anderton et al 2008; Kongham et al 2008).  
The MB epigenomic studies demonstrate that not only the genetic alteration can cause loss 
of control in a cell and transformation to a malignant cell but also other mechanism can 
cause malignancy, implicated epigenetic gene silencing as important mechanism of the 
tumor suppressor gene inactivation in MB. 
7. Summary 
The reported genetic alterations of MB, either chromosomal or molecular, are so far not 
specific.The main distinct subgroups are the Wnt and the SHH both account for 30-40% of 
MB. These pathways are common in many other tumors, suggesting they are not exclusive 
to MB. There are some other pathways involved in MB pathogenesis that might be more 
specific to MB. Similarly, the chromosomal aberration i(17q) which is found in about 40% of 
MBs, as well as in many other tumors including in chronic myelocytic leukemia (CML) can 
possibly be a secondary chromosomal aberration. Some of the features found in different 
subtypes but not in an equal distribution, for instance i(17q) were found in 34% ,36%,12%  in 
classic ,large cell and desmoplastic MB respectively and are associate with poor prognosis 
(Gillbertson & Ellison 2008). Another example NOTCH and PDGF, they both have been 
found in A and B Kool's subtypes and also subtypes C, D and E  share increased expression 
of neural differentiation genes. Another example is the Wnt-β catenin, found in all subtypes 
defined in Northcott's classification. This overlapping between the different subtypes, points 
toward the fact that some of the alterations are not, necessarily, a specific prognostic marker.  
Studies have been done on a mice model and on cell lines in order to learn more about 
pathogenesis of MB are important; however the data learned from these experimental 
systems should be first corroborated with the data learned from human primary MBs, 
before going to conclusions on the pathogenesis of human MB. This is the reason for 
focusing in this chapter mainly on the studies done on primary human MBs studies.   
Due to the variable results, the exact and specific chromosomal changes in MB which is a 
crucial event in pathogenesis, is still unknown.  
Gilberston and Ellison (2008) wrote in their review: "Genomic-seeing the wood and the 
trees". The literature is full of studies (over 200 papers) on genetic alteration in MB trying to 
understand the MB pathogenesis, some of them corroborate with each other. Most of the 
studies have been done from different research points of view and emphasis, using different 
technologies. Presently, there are at least 5 different suggestions for classification and 
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stratification of MB: Thompson's (2006), WHO (2007), Kool's (2008), Pefister's (2008) and 
Northcott's (2011). It is very difficult to combine them to one clear cut classification (Table 1).  
 
*THOMPSON'S 
(2006) 
CLASSIFICATION 
(46) 
WHO 
 CLASSI-
FICATION 
PROGNOSIS 
MOLECULAR 
ALTERATION
CHROMO-
SOMAL 
ABERRATION
AGE OF 
ONSET 
A Gain:17q
Loss: 17p
 
B Classic MB Favorable Wnt- β 
catenin↑ 
CTNNB1-
predominant,A
PC, 
AXIN!mutation
Monosomy 6 ≥3 years 
C SHH
PTCH,SUFU 
mutation
Gain:17q
Loss: 17p 
 
D Desmoplastic SHH,
PTCH,SUFU 
mutation
≤3 years 
E Gain:17q
Loss: 17p 
 
*KOOL'S(2008) 
CLASSIFICATION 
(52) 
WHO  
CLASSI-
FICATION 
PROGNOSIS 
MOLECULAR 
ALTERATION
CHROMO-
SOMAL 
ABERRATION
AGE OF 
ONSET 
A classic Wnt
β-catenin 
mutation 
NOTCH, 
PDGF
Monosomy 6 Older 
children 
B desmoplastic SHH
PTCH1 
mutation 
NOTCH, 
PDGF
9q loss Young 
children 
years and 
adults 
C classic metastases Neural
differentiation 
genes 
17 alteration, 
loss of X 
chromosome 
(females)
children 
D classic metastases Neural 
differentiation 
genes 
Photoreceptor 
genes
17 alteration, 
loss of X 
chromosome 
(females 
children 
E classic metastases Photoreceptor 
genes 
loss of X 
chromosome 
(females
Young 
children 
*PFISTER'S(2009) 
CLASSIFICATION 
(80/260) 
WHO 
CLASSI-
FICATION 
PROGNOSIS Frequency  OS 
MYC/MYCN 
amplification+10ch.
Large 
cell/anaplastic
Poor prognosis 
methastases 
6%/4%/10%  13% 
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aber./ MYC/MYCN 
amplification  
+6q-gain+17qgain 
+10ch.aber. 
6q-gain+10ch.aber.  Poor prognosis 8%  16% 
17q-gain/17p-
loss/i(17q) 
+7.5ch.aber. 
 Poor prognosis 48%/39%/30-
48% 
 56% 
6q ,17qbalanced 
+4ch.aber. 
    90% 
6qdeletion 
+2ch.aber. 
 Favorable 
prognosis 
12%  100% 
*NORTHCOTT'S 
(2010)  
CLASSIFICATION 
(103)** 
WHO  
CLASSI-
FICATION 
PROGNOSIS 
MOLECULAR 
ALTERATION
CHROMO-
SOMAL 
ABERRATION
AGE OF 
ONSET 
Wnt   MYC↑ 
Wnt-β catenin
 
Monosomy 6 Distributed 
age median 
9-10 years, 
3:1 F/M 
SHH 
 
Desmoplastic-
predominant 
Anaplastic, 
large cell 
 MYCN↑ 
Wnt-β catenin
Del9q 
Isochromosome 
9p 
Gain: 3q, 20q, 
21q,2 
Loss:10q,14 
Infants ≤3 
years-most 
common, 
adults≥16 
years 
C Desmoplastic 
Anaplastic, 
large cell(23%)
Metastases(46.5
%) 
Worst prognosis
OTX2↑,FOXG1
B↑, 
MYC(8q24)↑, 
Wnt-β catenin
Neural 
development*
Isochromosome 
(17q) 
Gain:1q,17q,8 
Loss:10q, 
5qdistal, 
16q,11p ,8p 
Childhood 
peak 3-10 
years 
D Desmoplastic 
Anaplastic, 
large cell (8%)
Metastases(29.7
%) 
OTX2↑,FOXG1
B↑ Wnt-β 
catenin, 
Neural 
development*
Isochromosome 
(17q) 
Gain: 17q,8 
Loss:11p 
,X(females), 
8p,8q 
Distributed 
age median 
9-10 years 
WHO (2007): Classic, desmoplastic, MB with extensive nodularity, anaplastic, Large cell 
*For more details see: Louis 2007, Thompson et al 2006, Kool et al 2008, Pifster et al 2009, Northcott et al 
2010 J. Clin.Oncol., Parenthesis-Year of publication.  
** See table 2 in Ellison 2010, Table 2 in Huse and Holland 2010, Table 1-Northcott 2010 J. Clin.Oncol. 
Parenthesis –Number of samples 
Table 1. Medulloblastoma classification according to: WHO- Louis et al 2007, Thompson et al 
2006, Kool et al 2008, Pifster et al 2009, Northcott  et al 2011. 
There is also early evidences that epigenetics and miRs might play a role in MB pathogenesis 
and can be used as a prognostic tool. However , the data regarded to epigenetics and miRs  in 
MB is still limited and uncompleted, as part of the studies done on MB cell line which might 
point to a candidate involved genes with no assurance for there role in the MB tumor. There 
are few studies on primary MBs, thus any conclusion from this data is still immature. This 
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emphasized the need for further studying the MB pathogenesis for either specific germ line 
mutation or other specific level of alteration (transcriptome, proteome, epigenome levels). 
These should be done as a multi-center study , on a large size of cohort including sufficient 
number of samples of each MB subtype including adult and childhood MBs. The study should 
be performed uniformly using different levels of examinations: histologic, cytogenetic, 
molecular, transcriptome, proteome, epigennetics, and miRs. Hopefully such a study will 
provide us with more personalized medical care with less adverse side effects.   
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